Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kynexis B.V.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has an established primary psychiatric diagnosis of schizophrenia
Clinically stable and in the residual (nonacute) phase of their illness for at least 8 weeks before screening in the judgement of the investigator
Diagnosis of schizophrenia for at least 1 year before screening
Must be in ongoing maintenance antipsychotic monotherapy on a stable medication treatment regimen for ≥ 2 months before screening, including concomitant psychotropic medications.
Male or female, aged ≥18 and ≤55 years
Has a body mass index (BMI) between 18 and 40 kg/m2 Inclusive
Must exhibit capability to comply with all protocol procedures in the judgement of the investigator
Signed and dated written informed consent before screening in accordance with Good Clinical Practice.
You may not be if
Currently being treated with more than 1 antipsychotic at the time of screening,
A score of 2 or higher on any of the individual items of the Modified Simpson-Angus Scale (mSAS) at screening
Moderate to severe substance use disorder (other than nicotine or caffeine, but including alcohol)
Evidence of unstable medical condition
Clareo Health | A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
